Clinical Trials Logo

Filter by:
NCT ID: NCT03720704 Active, not recruiting - Clinical trials for Peripheral Vascular Diseases

Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels

EXPAND
Start date: December 18, 2018
Phase:
Study type: Observational [Patient Registry]

The primary objective of the VBX 17-04 registry is to collect post-market safety and performance data of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) in peripheral vessels in patients who require interventional treatment

NCT ID: NCT03720314 Completed - Clinical trials for Irritable Bowel Syndrome

Microbiota Profiling in IBS

IBSQUtrition
Start date: September 6, 2018
Phase:
Study type: Observational

This study investigates differences in microbiota profiles and metabolite levels between mild and severe IBS patients, compared to matched healthy controls. Two fecal samples, with one month in between, will be analyzed. Secondary parameters such as dietary intake, quality of life and stool pattern will be assessed.

NCT ID: NCT03719690 Completed - HNSCC Clinical Trials

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

AIM-HN/SEQ-HN
Start date: March 15, 2019
Phase: Phase 2
Study type: Interventional

An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study including HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.

NCT ID: NCT03719040 Completed - Heart Failure Clinical Trials

Physiologic Pacing Registry

Start date: November 27, 2018
Phase:
Study type: Observational [Patient Registry]

The Physiologic Pacing Registry is a prospective, observational, multi-center registry performed to gain a broader understanding of 1) physiologic pacing implant and follow-up workflows, including pacing and sensing measurements and 2) the clinical utility in creating a 3-dimensional electro-anatomical map of cardiac structures prior to physiologic pacing device implants based on the clinical site's routine care.

NCT ID: NCT03715894 Completed - Clinical trials for Aortic Valve Stenosis

Prospective Arm of Conduct - Edwards SAPIEN3 PPI Registry

Conduct-pro
Start date: December 1, 2018
Phase:
Study type: Observational

There are procedure related risk factors for permanent pacemaker implantation (PPI) that can be identified and assessed in a prospective cohort of 300 patients at high risk for PPI Prospective, multicenter, European registry in patients at high risk for PPI undergoing TAVI with the Edwards SAPIEN 3 valve. Additional assessment of calcification using a CT data core lab. Statistical analysis of the dataset obtained with respect to the objectives of the registry.

NCT ID: NCT03715166 Terminated - Clinical trials for Autism Spectrum Disorder (ASD)

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

Start date: September 24, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

NCT ID: NCT03714646 Completed - Obesity Clinical Trials

Beta Glucan and Acetate Production

Start date: September 5, 2018
Phase: N/A
Study type: Interventional

Based on our hypothesis that orally administered resistant starch and beta glucan will be fermented into a SCFA pattern high in acetate and that this will lead to beneficial effects on human substrate and energy metabolism, we aim to address the following primary objective: To investigate the effects of an acute administration of inulin/beta glucan in combination with resistant starch on fecal and plasma acetate, as well as on fasting and postprandial substrate and energy metabolism in lean normoglycemic men and obese, prediabetic men.

NCT ID: NCT03713632 Completed - Clinical trials for Hidradenitis Suppurativa

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

SUNRISE
Start date: February 25, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study assessed the safety and tolerability of secukinumab.

NCT ID: NCT03712423 Completed - Solid Tumor Clinical Trials

PET Study With [89Zr]-Df-CriPec® Docetaxel

Start date: April 1, 2018
Phase: Phase 1
Study type: Interventional

A clinical phase I, open-label PET study with [89Zr]-Df-CriPec® docetaxel in patients with solid tumours to assess biodistribution and tumour accumulation of [89Zr]-Df-CriPec® docetaxel.

NCT ID: NCT03712306 Completed - Physical Disability Clinical Trials

The (Cost)Effectiveness of Increasing Protein Intake on Physical Funtioning in Older Adults

Start date: October 11, 2018
Phase: N/A
Study type: Interventional

In this RCT with the duration of 6 months among 264 community-dwelling older adults (65+ years) with habitual low protein intake, the investigators will examine the long term (cost) effectiveness of increasing daily protein intake to at least 1.2 gram/kg of adjusted body weight on physical functioning in older adults with low protein intake.